Cyclo Therapeutics Inc.

10.81+0.0300+0.28%Vol 387.05K1Y Perf 149.28%
Jun 14th, 2021 16:00 DELAYED
BID10.35 ASK11.00
Open11.10 Previous Close10.78
Pre-Market- After-Market-
 - -  - -%
Target Price
25.00 
Analyst Rating
— — 0.00
Potential %
131.27 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     48.34
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★     52.23
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap68.74M 
Earnings Rating
Price Range Ratio 52W %
51.13 
Earnings Date
21st May 2021

Today's Price Range

10.1811.38

52W Range

3.5517.75

5 Year PE Ratio Range

-5.00-5.80

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
21.05%
1 Month
54.43%
3 Months
6.19%
6 Months
171.61%
1 Year
149.28%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CYTH10.810.03000.28
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Financial StrengthValueIndustryS&P 500US Markets
4.20
4.90
0.01
0.01
-
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
92.00
-1 106.60
-1 105.20
-720.00
-
RevenueValueIndustryS&P 500US Markets
935.78K
0.15
-5.62
-6.85
Earnings HistoryEstimateReportedSurprise %
Q01 2021--0.76-
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume387.05K
Shares Outstanding6.36M
Trades Count2.52K
Dollar Volume2.22M
Avg. Volume797.19K
Avg. Weekly Volume1.23M
Avg. Monthly Volume663.08K
Avg. Quarterly Volume527.78K

Cyclo Therapeutics Inc. (NASDAQ: CYTH) stock closed at 10.81 per share at the end of the most recent trading day (a 0.28% change compared to the prior day closing price) with a volume of 387.49K shares and market capitalization of 68.74M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Cyclo Therapeutics Inc. CEO is N. Scott Fine.

The one-year performance of Cyclo Therapeutics Inc. stock is 149.28%, while year-to-date (YTD) performance is 148.51%. CYTH stock has a five-year performance of %. Its 52-week range is between 3.55 and 17.75, which gives CYTH stock a 52-week price range ratio of 51.13%

Cyclo Therapeutics Inc. currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 4.79, a price-to-sale (PS) ratio of 73.45, a price to cashflow ratio of 63.20, a PEG ratio of 2.32, a ROA of -101.28%, a ROC of -160.83% and a ROE of -163.89%. The company’s profit margin is -%, its EBITDA margin is -1 105.20%, and its revenue ttm is $935.78 Thousand , which makes it $0.15 revenue per share.

Of the last four earnings reports from Cyclo Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cyclo Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cyclo Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Cyclo Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cyclo Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cyclo Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 55.21, ATR14 : 0.98, CCI20 : 187.49, Chaikin Money Flow : -0.29, MACD : 0.63, Money Flow Index : 85.78, ROC : 40.39, RSI : 76.29, STOCH (14,3) : 62.18, STOCH RSI : 1.00, UO : 47.86, Williams %R : -37.82), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cyclo Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its lead drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.

CEO: N. Scott Fine

Telephone: +1 386 418-8060

Address: 6714 NW 16th Street, Gainesville 32653, FL, US

Number of employees: 8

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits